Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry

- Gibson, P. G., Reddel, H., Katsoulotos, G. P., Cook, M., Yang, I., Katelaris, C., Bowler, S., Langton, D., Robinson, P., Wright, C., Yozghatlian, V., Burgess, S., McDonald, V. M., Sivakumaran, P., Jaffe, A., Bowden, J., Wark, P. A. B., Yan, K. Y., Kritikos, V., Peters, M., Hew, M., Aminazad, A., Bint, M., Marks, G., Guo, M., Jenkins, C., Gillman, A., Upham, J., Sutherland, M., Rimmer, J., Thien, F.

Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria

- Hew, M., Gillman, A., Rimmer, J., Katsoulotos, G. P., Cook, M., Yang, I., Katelaris, C., Bowler, S., Langton, D., Wright, C., Bint, M., Yozghatlian, V., Sutherland, M., Powell, H., McDonald, V. M., Gibson, P. G., Wark, P., Bowden, J., Guo, M., Reddel, H. K., Jenkins, C., Marks, G. B., Thien, F.